SCHEMBL16767853

SCHEMBL16767853

CCc1cccc2[nH]c(=O)c(O)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DAO P14920 11/20 1.00
DDO Q99489 5/20 1.00
NPEPPS P55786 1/20 0.47
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.45
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GRIN3A Q8TCU5 1/20 0.44
MAPT P10636 1/20 0.43
IDE P14735 1/20 0.43
MPI P34949 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11115863 0.83 DAO (0.70) DAODDOKDM4EALDH1A1MAPT
SCHEMBL15713795 0.81 DAO (0.68) DAODDOKDM4EALDH1A1MAPT
SCHEMBL9389830 0.81 DAO (0.68) DAODDOGRIN2DGRIN3BGRIN1
SCHEMBL3423807 0.79 DAO (1.00) DAODDOKDM4EALDH1A1MAPT
SCHEMBL3363456 0.76 DAO (1.00) DAODDOKDM4EALDH1A1MAPT
SCHEMBL16767849 0.76 DAO (1.00) DAODDOKDM4EALDH1A1HPGD
SCHEMBL15690473 0.76 DAO (0.65) DAODDOKDM4EALDH1A1MAPT
SCHEMBL3363146 0.75 DAO (0.60) DAODDOGRIN2DGRIN3BGRIN1
SCHEMBL15108883 0.75 DAO (0.60) DAODDONPEPPSKDM4EALDH1A1
SCHEMBL14531557 0.75 DAO (0.60) DAODDONPEPPSKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9468669-B2 Methods to treat dysregulated blood glucose disorders REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2016-10-18 US disclosed
US-9468669-B2 Methods to treat dysregulated blood glucose disorders REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2016-10-18 US disclosed
US-20160228515-A1 METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2016-08-11 US disclosed
US-20160228515-A1 METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2016-08-11 US disclosed
US-9339482-B2 Methods to treat dysregulated blood glucose disorders REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2016-05-17 US disclosed
US-9339482-B2 Methods to treat dysregulated blood glucose disorders REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2016-05-17 US disclosed
US-20150150836-A1 METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS REGENTS OF THE UNIVERSITY OF MINNESOTA 2015-06-04 US disclosed
US-20150150836-A1 METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS REGENTS OF THE UNIVERSITY OF MINNESOTA 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150836-A1 METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS SLC2A4, SLC2A2, SLC2A3 DAO 3050/4885DDO 2128/4885NPEPPS 3905/4885
US-20160228515-A1 METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS SLC2A4, SLC2A2, SLC2A3 DAO 3050/4885DDO 2128/4885NPEPPS 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.